In particular, combinatorial therapies similar to those used to treat cancer, are promising, but the efficacy of NRF2 inducers combined with known SCD drugs, such as HU, needs to be determined through further research. The gene discussed is NFE2L2; the disease is Schnyder corneal dystrophy.